The Eppendorf Group and LabCentral have renewed their decade-long relationshipfor an additional five years.
Strategically placed Eppendorf equipment and consumables at LabCentral enables reliable results for startups, contributing to scientific milestones to being reached quicker.
Hamburg/ Cambridge, March 27, 2024 – The globally active Eppendorf Group proudly an nounces the 5-year partnership renewal with LabCentral, a renowned life sciences incuba tor, dedicated to empowering innovative biotech startups. As a Partner since 2014 and Founding Sponsor since 2019, the Eppendorf Group continues its commitment to fostering scientific breakthroughs and supporting the next generation of biotech innovators.
"Eppendorf is proud to continue its relationship as a Founding Sponsor with LabCentral, affirming our shared vision for advancing scientific excellence and empowering researchers to make groundbreak ing discoveries", says Dennis Barger, President Market Region Americas, Eppendorf. "Together, we continue to shape the future of life sciences, where collaboration is the catalyst for transformative breakthroughs."
LabCentral is a community of entrepreneurs and scientists dedicated to creating the next generation of groundbreaking science and technology. The Eppendorf Group is a leading life science company that develops, produces, and distributes systems for use in laboratories around the world. Through the partnership, the Eppendorf Group provides a range of equipment, including freezers, shakers, in cubators, cyclers, centrifuges, automation, bioprocess, and pipettes, placed within LabCentral's shared facilities. This provides startups immediate access to high quality instrumentation, ensuring they can run experiments day one of residency.
"As a longtime strategic Founding Sponsor to LabCentral, Eppendorf has built a strong reputation for excellence both inside our labs as well as in our resident community", shares Johannes Fruehauf, MD, PhD, President and Executive Director LabCentral. "We are thrilled to extend this collaboration to wards our shared mission to improve human health by building biotechs better, faster, and more effi ciently."
LabCentral occupies six sites in Massachusetts, USA, continually expanding since being established in 2013. 21% of biopharma Series A funds in 2022 in the US has been awarded to companies affiliated with LabCentral and its resident and alumni companies have raised nearly $23 billion in total funding, creating 5,800 new jobs since 2013. The premier shared lab community is home to more than 100 companies ranging from a single employee to teams of 30 or more. LabCentral offers an ideal space and infrastructure for biotech startups to focus on building their company and developing their science. The future of medicine starts at this leading incubator with the resident innovators and Eppendorf as a premium solutions provider.
